{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:52:32Z","timestamp":1791078752282,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2012,10,8]],"date-time":"2012-10-08T00:00:00Z","timestamp":1349654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The efficacy of 3 years of annual intravenous administration of zoledronic acid (ZOL) in reducing vertebral and nonvertebral fractures in postmenopausal osteoporosis has been shown by the HORIZON pivotal fracture trial. Histomorphometric analysis of transiliac bone biopsies from the HORIZON participants revealed significantly improved trabecular architecture and reduced bone remodeling for the ZOL-treated versus placebo-treated patients. The aim of our study was to evaluate the cancellous and cortical bone mineralization density distribution (BMDD) in these biopsies by quantitative backscattered electron imaging (qBEI). The study cohort comprised 82 patients on active treatment (ZOL, yearly doses of 5\u2009mg) and 70 treated with placebo, and all received adequate Ca and VitD supplementation. Comparison of ZOL-treated versus placebo-treated cancellous (Cn.) and cortical (Ct.) BMDD-derived variables resulted in significantly higher average (Cn.CaMean\u2009+\u20093.2%, Ct.CaMean\u2009+\u20092.7%) and mode calcium concentrations (Cn.CaPeak\u2009+\u20092.1%, Ct.CaPeak\u2009+\u20091.5%), increased percentages of highly mineralized bone areas (Cn.CaHigh\u2009+\u200964%, Ct.CaHigh\u2009+\u200931%), lower heterogeneity of mineralization (Cn.CaWidth \u221214%, Ct.CaWidth \u221213%), and decreased percentages of low mineralized bone areas (Cn.CaLow \u221222%, Ct.CaLow \u221226%) versus placebo (all p\u2009&amp;lt;\u20090.001). Cn. BMDD from the patients on active treatment also revealed a statistically significant shift to higher Ca concentrations when compared to a historical normal reference BMDD. These differences in BMDD from ZOL patients compared to the other groups were in line with the correlation of BMDD variables with previously determined cancellous mineralizing surface per bone surface (Cn. MS\/BS, a primary histomorphometric index for bone turnover), showing that those with lower Cn. MS\/BS had a higher degree of bone matrix mineralization. However, the differences in BMDD variables between the study groups remained when adjusted for Cn. MS\/BS, suggesting that other factors in addition to reduced bone turnover might contribute to the higher bone matrix mineralization after ZOL treatment. \u00a9 2013 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.1780","type":"journal-article","created":{"date-parts":[[2012,10,8]],"date-time":"2012-10-08T18:41:26Z","timestamp":1349721686000},"page":"442-448","source":"Crossref","is-referenced-by-count":26,"title":["Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort"],"prefix":"10.1093","volume":"28","author":[{"given":"Barbara M","family":"Misof","sequence":"first","affiliation":[{"name":"Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Roschger","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios P","family":"Paschalis","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik F","family":"Eriksen","sequence":"additional","affiliation":[{"name":"Hormonlaboratoriet, AUS Aker Universitetssykehus Trondheimsveien, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R","family":"Recker","sequence":"additional","affiliation":[{"name":"Creighton University School of Medicine, Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrg A","family":"Gasser","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Klaushofer","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,10,8]]},"reference":[{"issue":"18","key":"2024020318424055600_bib1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"issue":"18","key":"2024020318424055600_bib2","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMe078051","article-title":"Treatments for osteoporosis: looking beyond the HORIZON","volume":"356","author":"Compston","year":"2007","journal-title":"N Engl J Med."},{"issue":"9","key":"2024020318424055600_bib3","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2008-2765","article-title":"Cauley JA; HORIZON Pivotal Fracture Trial. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density","volume":"94","author":"Eastell","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2024020318424055600_bib4","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00198-009-1077-9","article-title":"Black DM; HORIZON Pivotal Fracture Trial. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial","volume":"21","author":"Eastell","year":"2010","journal-title":"Osteoporos Int."},{"issue":"1","key":"2024020318424055600_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1359\/jbmr.070906","article-title":"Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure","volume":"23","author":"Recker","year":"2008","journal-title":"J Bone Miner Res."},{"key":"2024020318424055600_bib6","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bone.2007.10.021","article-title":"Bone mineralization density distribution in health and disease","volume":"42","author":"Roschger","year":"2008","journal-title":"Bone."},{"key":"2024020318424055600_bib7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S8756-3282(02)00973-0","article-title":"Constant mineralization density distribution in cancellous human bone","volume":"32","author":"Roschger","year":"2003","journal-title":"Bone."},{"key":"2024020318424055600_bib8","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.bone.2007.01.012","article-title":"The bone mineralization density distribution as a fingerprint of the mineralization process","volume":"40","author":"Ruffoni","year":"2007","journal-title":"Bone."},{"key":"2024020318424055600_bib9","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1359\/jbmr.080711","article-title":"Effect of temporal changes in bone turnover on the bone mineralization density distribution: a computer simulation study","volume":"23","author":"Ruffoni","year":"2008","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024020318424055600_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S8756-3282(01)00485-9","article-title":"Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women","volume":"29","author":"Roschger","year":"2001","journal-title":"Bone."},{"key":"2024020318424055600_bib11","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1359\/jbmr.060401","article-title":"Effects of 3- and 5-year treatment with risedronate on the bone mineral density distribution of cancellous bone in human iliac crest biopsies","volume":"21","author":"Zoehrer","year":"2006","journal-title":"J Bone Miner Res."},{"key":"2024020318424055600_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin","year":"2000","journal-title":"Bone."},{"key":"2024020318424055600_bib13","first-page":"538","article-title":"Effects of bisphosphonates on matrix mineralization","volume":"2","author":"Boivin","year":"2002","journal-title":"J Musculoskelet Neuronal Interact."},{"key":"2024020318424055600_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bone.2006.01.161","article-title":"Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography","volume":"39","author":"Borah","year":"2006","journal-title":"Bone."},{"key":"2024020318424055600_bib15","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1359\/jbmr.2002.17.8.1372","article-title":"Synchrotron radiation microtomography allows the analysis of three-dimensional microarchitecture and degree of mineralization of human iliac crest biopsy specimens: effect of etidronate treatment","volume":"17","author":"Nuzzo","year":"2002","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2024020318424055600_bib16","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1210\/jc.2002-021988","article-title":"Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment","volume":"88","author":"Misof","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2024020318424055600_bib17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1359\/jbmr.091028","article-title":"Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment","volume":"25","author":"Roschger","year":"2010","journal-title":"J Bone Miner Res."},{"key":"2024020318424055600_bib18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S8756-3282(98)00112-4","article-title":"Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies","volume":"23","author":"Roschger","year":"1998","journal-title":"Bone."},{"key":"2024020318424055600_bib19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00223-008-9161-2","article-title":"Short-term effects of high-dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation","volume":"83","author":"Misof","year":"2008","journal-title":"Calcif Tissue Int."},{"issue":"2","key":"2024020318424055600_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jbmr.5650030203","article-title":"Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females","volume":"3","author":"Recker","year":"1988","journal-title":"J Bone Miner Res."},{"key":"2024020318424055600_bib21","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Invest."},{"key":"2024020318424055600_bib22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1359\/jbmr.071101","article-title":"Positive effects of intravenous zoledronic acid on bone remodeling and structure: are different effects on osteoblast activity to other oral bisphosphonates responsible?","volume":"23","author":"Ebeling","year":"2008","journal-title":"J Bone Miner Res."},{"key":"2024020318424055600_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/jbmr.180","article-title":"Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly zoledronic acid","volume":"26","author":"Gamsjaeger","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020318424055600_bib24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone."},{"key":"2024020318424055600_bib25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1359\/jbmr.070120","article-title":"New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging","volume":"22","author":"Roschger","year":"2007","journal-title":"J Bone Miner Res."},{"key":"2024020318424055600_bib26","article-title":"Bone material properties in premenopausal women with idiopathic osteoporosis","volume":"6","author":"Misof","year":"2012","journal-title":"J Bone Miner Res. Epub."},{"key":"2024020318424055600_bib27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jbmr.320","article-title":"The amazing osteocyte","volume":"26","author":"Bonewald","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"8","key":"2024020318424055600_bib28","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s00198-012-1915-z","article-title":"Osteocyte regulation of bone mineral: a little give and take","volume":"23","author":"Atkins","year":"2012","journal-title":"Osteoporos Int."},{"key":"2024020318424055600_bib29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jor.21229","article-title":"Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis","volume":"29","author":"Brennan","year":"2011","journal-title":"J Orthop Res."},{"key":"2024020318424055600_bib30","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.bone.2011.07.017","article-title":"Issues in modern bone histomorphometry","volume":"49","author":"Recker","year":"2011","journal-title":"Bone."},{"issue":"2","key":"2024020318424055600_bib31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.1780","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/3\/442\/56563941\/1780_ftp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/3\/442\/56563941\/1780_ftp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:47:59Z","timestamp":1710341279000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/28\/3\/442-448\/7598728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,8]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,10,8]]},"published-print":{"date-parts":[[2013,3,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.1780","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,3,1]]},"published":{"date-parts":[[2012,10,8]]}}}